Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Mené sur des patients atteints d'un mélanome métastatique de l'uvée et positifs à l’antigène leucocytaire humain HLA-A*02:01 (durée minimale de suivi : 36 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie globale à 3 ans, et la toxicité du tebentafusp (une protéine bispécifique associant un récepteur de lymphocytes T et un anti-CD3)
Résumé en anglais
Background: Tebentafusp, a T-cell receptor–bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive for HLA-A*02:01 and have unresectable or metastatic uveal melanoma. The primary analysis in the present phase 3 trial supported a long-term survival benefit associated with the drug.
Methods: We report the 3-year efficacy and safety results from our open-label, phase 3 trial in which HLA-A*02:01–positive patients with previously untreated metastatic uveal melanoma were randomly assigned in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator’s choice of therapy with pembrolizumab, ipilimumab, or dacarbazine (control group), with randomization stratified according to the lactate dehydrogenase level. The primary end point was overall survival.
Results: At a minimum follow-up of 36 months, median overall survival was 21.6 months in the tebentafusp group and 16.9 months in the control group (hazard ratio for death, 0.68; 95% confidence interval, 0.54 to 0.87). The estimated percentage of patients surviving at 3 years was 27% in the tebentafusp group and 18% in the control group. The most common treatment-related adverse events of any grade in the tebentafusp group were rash (83%), pyrexia (76%), pruritus (70%), and hypotension (38%). Most tebentafusp-related adverse events occurred early during treatment, and no new adverse events were observed with long-term administration. The percentage of patients who discontinued treatment because of adverse events continued to be low in both treatment groups (2% in the tebentafusp group and 5% in the control group). No treatment-related deaths occurred.
Conclusions: This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01–positive patients with previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202 ClinicalTrials.gov number, NCT03070392. opens in new tab; EudraCT number, 2015-003153-18. opens in new tab.)
